The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
Clinical Aspects of Immunology.
(1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-71-1-229_2 · Cited by 1,527
Anderson, P. C. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03520040082051 · Cited by 896
THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS
Rowinsky, M. (1997) · Annual Review of Medicine · doi:10.1146/annurev.med.48.1.353 · Cited by 721
Sparreboom, A., Scripture, C. D., Trieu, V., Williams, P. J., De, T., Yang, A., Beals, B., Figg, W. D., Hawkins, M., & Desai, N. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2291 · Cited by 504
Polymeric Micelles for Delivery of Poorly Water-Soluble Compounds
Kwon, G. S. (2003) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v20.i5.20 · Cited by 502
Chanan-Khan, A., Szebeni, J., Savay, S., Liebes, L., Rafique, N. M., Alving, C. R., & Muggia, F. M. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg374 · Cited by 479
Self-citationGabizon, A., & Martin, F. (1997) · Drugs · doi:10.2165/00003495-199700544-00005 · Cited by 478
Uziely, B., Jeffers, S., Isacson, R., Kutsch, K., Wei-Tsao, D., Yehoshua, Z., Libson, E., Muggia, F. M., & Gabizon, A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1777 · Cited by 477
Gill, P. S., Wernz, J., Scadden, D. T., Cohen, P., Mukwaya, G. M., von Roenn, J. H., Jacobs, M., Kempin, S., Silverberg, I., Gonzales, G., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.8.2353 · Cited by 438
Cardiac disturbances during the administration of taxol.
Rowinsky, E. K., McGuire, W. P., Guarnieri, T., Fisherman, J. S., Christian, M. C., & Donehower, R. C. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.9.1704 · Cited by 395
Taxol: the first of the taxanes, an important new class of antitumor agents.
Rowinsky, E. K., Onetto-Pothier, N., Canetta, R. M., & Arbuck, S. G. (1992) · PubMed · Cited by 389
Chonn, A., Cullis, P. R., & Devine, D. V. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.12.4234 · Cited by 367
Szebeni, J., Alving, C. R., & Muggia, F. M. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.4.300 · Cited by 341
Self-citationColloidal drug carriers: achievements and perspectives
Barratt, G. (2003) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s000180300002 · Cited by 333
Joining the DoTS: new approach to classifying adverse drug reactions
Aronson, J. K., & Ferner, R. E. (2003) · BMJ · doi:10.1136/bmj.327.7425.1222 · Cited by 297
Gabizón, A., & Martin, F. J. (1997) · Drugs · Cited by 293
Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin.
Gill, P. S., Espina, B. M., Muggia, F., Cabriales, S., Tulpule, A., Esplin, J. A., Liebman, H. A., Forssen, E., Ross, M. E., & Levine, A. M. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.4.996 · Cited by 242
Lorenz, W., Reimann, H. J., Schmal, A., Dormann, P., Schwarz, B., Neugebauer, E., & Doenicke, A. (1977) · Agents and Actions · doi:10.1007/bf01964882 · Cited by 219
Szebeni, J., Baranyi, L., Savay, S., Milosevits, J., Bunger, R., Laverman, P., Metselaar, J. M., Storm, G., Chanan-Khan, A., Liebes, L., et al. (2002) · Journal of Liposome Research · doi:10.1081/lpr-120004790 · Cited by 212
Self-citationAlberts, D. S., & Garcia, D. J. (1997) · Drugs · doi:10.2165/00003495-199700544-00007 · Cited by 182
Szebeni, J., Fontana, J. L., Wassef, N. M., Mongan, P. D., Morse, D. S., Dobbins, D. E., Stahl, G. L., Bünger, R., & Alving, C. R. (1999) · Circulation · doi:10.1161/01.cir.99.17.2302 · Cited by 176
Self-citationWinkler, G. C. (1988) · American Journal of Anatomy · doi:10.1002/aja.1001810302 · Cited by 174
Szebeni, J., Baranyi, L., Savay, S., Bodo, M., Morse, D. S., Basta, M., Stahl, G. L., Bünger, R., & Alving, C. R. (2000) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2000.279.3.h1319 · Cited by 171
Self-citationSzebeni, J. (2001) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v18.i6.50 · Cited by 147
Self-citationSzebeni, J., Alving, C. R., Sávay, S., Barenholz, Y., Priev, A., Danino, D., & Talmon, Y. (2001) · International Immunopharmacology · doi:10.1016/s1567-5769(01)00006-6 · Cited by 147
Self-citationMarked improvement of the basophil activation test by detecting CD203c instead of CD63
Boumiza, R., Monneret, G., Forissier, M.-F., Savoye, J., Gutowski, M. C., Powell, W. S., & Bienvenu, J. (2003) · Clinical & Experimental Allergy · doi:10.1046/j.1365-2222.2003.01594.x · Cited by 140
Nerurkar, M. M., Ho, N. F. H., Burton, P. S., Vidmar, T. J., & Borchardt, R. T. (1997) · Journal of Pharmaceutical Sciences · doi:10.1021/js960483y · Cited by 139
Gell and Coombs's classification: is it still valid?
Descotes, J., & Choquet‐Kastylevsky, G. (2001) · Toxicology · doi:10.1016/s0300-483x(00)00400-5 · Cited by 138
Long Circulating Liposomes: Old Drugs, New Therapeutics
Woodle, M. C., & Storm, G. (1998) · Springer eBooks · doi:10.1007/978-3-662-22115-0 · Cited by 137
Dams, E. T. M., Oyen, W. J. G., Boerman, O. C., Storm, G., Laverman, P., Kok, P. J., Buijs, W. C. A. M., Bakker, H. H., van der Meer, J. W., & Corstens, F. H. M. (2000) · PubMed · Cited by 130
Webster, L. K., Linsenmeyer, M. E., Millward, M., Morton, C. G., Bishop, J. F., & Woodcock, D. M. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.20.1685 · Cited by 128
The Interaction of Liposomes with the Complement System
Szebeni, J. (1998) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v15.i1.20 · Cited by 123
Self-citationHunter, R. L., & Bennett, B. T. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.133.6.3167 · Cited by 122
Moghimi, S. M., Hunter, A. C., Dadswell, C., Sávay, S., Alving, C. R., & Szebeni, J. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.02.005 · Cited by 120
Self-citationGreenberger, P. A. (1984) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(84)90113-1 · Cited by 116
Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions
Bookman, M. A., Kloth, D. D., Kover, P. E., Smolinski, S., & Ozols, R. F. (1997) · Annals of Oncology · doi:10.1023/a:1008207025430 · Cited by 114
Szebeni, J., Baranyi, L., Sávay, S., Bodó, M., Milosevits, J., Alving, C. R., & Bünger, R. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00622.2005 · Cited by 113
Self-citationSuccessful parenteral desensitization to paclitaxel
Essayan, D. M., Kagey‐Sobotka, A., Colarusso, P., Lichtenstein, L. M., Ozols, R. F., & King, E. D. (1996) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(96)70281-6 · Cited by 109
Alternative formulations of paclitaxel
Terwogt, J. M. M., Nuijen, B., Huinink, W. W. T. B., & Beijnen, J. H. (1997) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(97)90022-0 · Cited by 100
Activation of Serum Complement by Contrast Media
Lang, J. H., Lasser, E. C., & Kolb, W. P. (1976) · Investigative Radiology · doi:10.1097/00004424-197607000-00007 · Cited by 94
The Role of Complement Activation in Hypersensitivity to Pegylated Liposomal Doxorubicin (Doxil®)
Szebeni, J., Baranyi, L., Sávay, S., Lutz, H. U., Jelezarova, E., Bünger, R., & Alving, C. R. (2000) · Journal of Liposome Research · doi:10.3109/08982100009031112 · Cited by 93
Self-citationLundberg, B. B. (1997) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1997.tb06744.x · Cited by 89
The use of antihistamines in the prevention and treatment of anaphylaxis and anaphylactoid reactions
Lieberman, P. (1990) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(05)80241-6 · Cited by 86
Cardiopulmonary Toxicity after Liposomal Amphotericin B Infusion
Levine, S. J., Walsh, T. J., Martinez, A. D., Eichacker, P. Q., Lopez‐Berestein, G., & Natanson, C. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-8-664 · Cited by 84
Phase I and pharmacologie study of liposomal daunorubicin (DaunoXome)
Guaglianone, P. P., Chan, K. K., Delaflor–Weiss, E., Hanisch, R., Jeffers, S., Sharma, D., & Muggia, F. M. (1994) · Investigational New Drugs · doi:10.1007/bf00874439 · Cited by 81
The Interaction of Liposomes with the Complement System: In Vitro and In Vivo Assays
Szebeni, J., Baranyi, L., Sávay, S., Milosevits, J., Bodó, M., Bünger, R., & Alving, C. R. (2003) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(03)73010-9 · Cited by 79
Self-citationClinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: A review
Guchelaar, H., ten Napel, C. H. H., de Vries, E. G. E., & Mulder, N. H. (1994) · Clinical Oncology · doi:10.1016/s0936-6555(05)80367-x · Cited by 77
Predictive capacity of histamine release for the diagnosis of drug allergy
Demoly, P. M., Lebel, B., Messaad, D., Sahla, H., Rongier, M., Daurès, J., Godard, P., & Bousquet, J. J. (1999) · Allergy · doi:10.1034/j.1398-9995.1999.00020.x · Cited by 72
Pulmonary Infiltrates Following Administration of Paclitaxel
Ramanathan, R. K., Reddy, V. V., Holbert, J. M., & Belani, C. P. (1996) · CHEST Journal · doi:10.1378/chest.110.1.289 · Cited by 68
Immune response of a liposomal model membrane.
Haxby, J. A., Kinsky, C. B., & Kinsky, S. C. (1968) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.61.1.300 · Cited by 68
Anaphylactic reactions to liposomal amphotericin
Laing, R. B. S., Milne, L. J. R., Leen, C. L. S., Malcolm, G. P., & Steers, A. J. W. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92116-4 · Cited by 68
Smith, C. A., Vogel, C., & Müller‐Eberhard, H. J. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)33952-8 · Cited by 65
Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil???)
Skubitz, K. M., & Skubitz, A. P. N. (1998) · Anti-Cancer Drugs · doi:10.1097/00001813-199801000-00005 · Cited by 65
Antibody binding and complement fixation by a liposomal model membrane
Alving, C. R., Kinsky, S. C., Haxby, J. A., & Kinsky, C. B. (1969) · Biochemistry · doi:10.1021/bi00832a038 · Cited by 61
Tc-99m-PEG-Liposomes for the Evaluation of Colitis in Crohn's Disease
Brouwers, A. H., Jong, D. D., Dams, E. T. M., Oyen, W. J. G., Boerman, O. C., Laverman, P., Naber, A. H. J., Storm, G., & Corstens, F. H. M. (2000) · Journal of drug targeting · doi:10.3109/10611860008997901 · Cited by 61
Nonimmunologic Complement Activation in Normal Human Serum Induced by Radiographic Contrast Media
Kolb, W. P., Lang, J. H., & Lasser, E. C. (1978) · The Journal of Immunology · doi:10.4049/jimmunol.121.4.1232 · Cited by 60
Improved Paclitaxel Formulation Hints at New Chemotherapy Approach
Garber, K. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/96.2.90 · Cited by 55
Hypersensitivity Reactions to the Taxanes Paclitaxel and Docetaxel
Panday, V. R. N., Huizing, M. T., Huinink, W. W. T. B., Vermorken, J. B., & Beijnen, J. H. (1997) · Clinical Drug Investigation · doi:10.2165/00044011-199714050-00011 · Cited by 52
Szebeni, J., Wassef, N. M., Spielberg, H., Rudolph, A. S., & Alving, C. R. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2658 · Cited by 52
Self-citationPROPERTIES OF CREMOPHOR EL MICELLES PROBED BY FLUORESCENCE
Kessel, D. H. (1992) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.1992.tb02187.x · Cited by 49
LASSER, E. C., Lang, J. H., LYON, S. G., & Hamblin, A. E. (1980) · Investigative Radiology · doi:10.1097/00004424-198011001-00004 · Cited by 48
Allergic reactions and other rare side-effects of liposomal amphotericin
Ringdén, O. T. H., Andström, E. E., Remberger, M., Svahn, B. ‐., & Tollemar, J. G. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90663-7 · Cited by 47
Hypersensitivity reactions to radiocontrast media: The role of complement activation
Szebeni, J. (2004) · Current Allergy and Asthma Reports · doi:10.1007/s11882-004-0038-9 · Cited by 45
Self-citationVM-26 (Teniposide)-Induced Hypersensitivity and Degranulation of Basophils in Children
Nolle, H., Carstensen, H., & HERTZ, H. (1988) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-198824000-00007 · Cited by 43
Implications of the new FDA/CDER immunotoxicology guidance for drugs
Hastings, K. L. (2002) · International Immunopharmacology · doi:10.1016/s1567-5769(02)00061-9 · Cited by 40
Liposomal and lipid-based formulations of amphotericin B.
de Marie, S. (1996) · PubMed · Cited by 39
Anaphylactoid reactions to radiocontrast material
Lieberman, P. (1991) · Clinical Reviews in Allergy · doi:10.1007/bf02802311 · Cited by 37
Richardson, D. S., Kelsey, S. M., Johnson, S. A., Tighe, M., Cavenagh, J. D., & Newland, A. C. (1997) · Investigational New Drugs · doi:10.1023/a:1005879219554 · Cited by 34
Anaphylactoid reactions to radiocontrast material
Erffmeyer, J. E., Siegle, R. L., & Lieberman, P. (1985) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(85)90079-x · Cited by 34
Initial Clinical Evaluation of Pegylated-Liposomal Doxorubicin in Solid Tumors
Gabizón, A., & Muggia, F. M. (1998) · Springer eBooks · doi:10.1007/978-3-662-22115-0_11 · Cited by 32
Kessel, D. H., Woodburn, K. W., Decker, D., & Sykes, E. (1995) · PubMed · Cited by 29
Genovese, A., Stellato, C., Patella, V., Lamparter-Schummert, B., de Crescenzo, G., Adt, M., & Marone, G. (1996) · International Journal of Clinical & Laboratory Research · doi:10.1007/bf02592981 · Cited by 23
ANAPHYLACTIC REACTION TO LIPOSOMAL AMPHOTERICIN (AMBISOME)
Schneider, P., Klein, R. M., Dietze, L., Söhngen, D., Leschke, M., & Heyll, A. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.0952a.x · Cited by 22
Complement-Mediated Acute Effects of Liposome-Encapsulated Hemoglobin
Szebeni, J., & Alving, C. R. (1999) · Artificial Cells Blood Substitutes and Biotechnology · doi:10.3109/10731199909117481 · Cited by 20
Self-citation[The complement-activating action of modern x-ray contrast agents].
Napolov, I. K., Bolotova, E. N., & Nl, S. (1998) · PubMed · Cited by 6
Napolov, I. K. (1997) · PubMed · Cited by 4
Cited by
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533
Advances and Challenges of Liposome Assisted Drug Delivery
Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00286 · Cited by 2,632
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Recent advances in iron oxide nanocrystal technology for medical imaging☆
COROT, C., ROBERT, P., IDEE, J., & PORT, M. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.013 · Cited by 1,465
X-ray-Computed Tomography Contrast Agents
Lusic, H., & Grinstaff, M. W. (2013) · Chemical Reviews · doi:10.1021/cr200358s · Cited by 1,108
Metadata
- Authors
- Szebeni, J.
- Venue
- Toxicology
- Publisher
- Elsevier BV
- Published
- 2005-12
- Volume
- 216
- Issue
- 2-3
- Pages
- 106-121
- ISSN
- 0300-483X (ISSN-L)
- OpenAlex
- W2075020461
- Cited by
- 611
- References
- 77
- FWCI
- 2.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.